The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Meridian Bioscience's revenues will expand 2.6% and EPS will drop 0.0%.
The average estimate for revenue is $48.7 million. On the bottom line, the average EPS estimate is $0.23.
Last quarter, Meridian Bioscience chalked up revenue of $45.4 million. GAAP reported sales were 13% higher than the prior-year quarter's $40.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.20. GAAP EPS of $0.20 for Q1 were 25% higher than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 63.5%, 210 basis points better than the prior-year quarter. Operating margin was 28.9%, 340 basis points better than the prior-year quarter. Net margin was 18.7%, 240 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $189.4 million. The average EPS estimate is $0.87.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 463 members out of 475 rating the stock outperform, and 12 members rating it underperform. Among 118 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 115 give Meridian Bioscience a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Meridian Bioscience is hold, with an average price target of $20.43.
Is Meridian Bioscience the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Meridian Bioscience to My Watchlist.